This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax,
and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle
cell lymphoma (MCL).
The names of the study drugs involved in this study are:
- Acalabrutinib
- Venetoclax
- Obinutuzumab